Expect a Limited Role for the New COPD Drug, Yupelri
You'll see Yupelri (yoo-PEL-ree, revefenacin), the first ONCE-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD.
It will have an edge over TWICE-daily Lonhala Magnair (glycopyrrolate)...the only other nebulized LAMA.
Yupelri is given via a standard nebulizer. Lonhala requires its own Magnair nebulizer...which can't be used to nebulize other meds.